NOVARTIS

13 May 2021

Novartis Pharma AG
Basel, Switzerland
CH-4002

Reference: EudraCT 2015-005738-23

Novartis Protocol ID CBAF312AX2207

A phase II, patient- and investigator-blinded, randomized, placebo-controlled study to evaluate efficacy, safety and tolerability of BAF312 (siponimod) in patients with stroke due to intracerebral hemorrhage (ICH)

No patients from the European Union were enrolled into Trial 2015-005738-23, therefore, no results will be reported.